Abeona Therapeutics (NASDAQ:ABEO) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Abeona Therapeutics (NASDAQ:ABEO) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.19, Zacks reports.

Abeona Therapeutics Stock Up 0.2 %

Shares of Abeona Therapeutics stock opened at $5.15 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. Abeona Therapeutics has a 1 year low of $3.05 and a 1 year high of $8.45. The firm’s 50-day moving average is $5.44 and its two-hundred day moving average is $5.83. The stock has a market cap of $223.88 million, a price-to-earnings ratio of -1.91 and a beta of 1.79.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ABEO. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, February 19th. StockNews.com cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 22nd. Finally, Oppenheimer initiated coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target on the stock. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $17.50.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.